These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 25998436

  • 1. Preparation and immunogenicity-evaluation of typhoid O-specific polysaccharides bio-conjugate vaccines.
    Peng ZH, Pan C, Sun P, Feng EL, Wu J, Zhu L, Peng QZ, Wang HL.
    Yi Chuan; 2015 May; 37(5):473-9. PubMed ID: 25998436
    [Abstract] [Full Text] [Related]

  • 2. First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.
    Salman M, St Michael F, Ali A, Jabbar A, Cairns C, Hayes AC, Rahman M, Iqbal M, Haque A, Cox AD.
    J Immunol Methods; 2017 Nov; 450():27-33. PubMed ID: 28735760
    [Abstract] [Full Text] [Related]

  • 3. Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children.
    Canh DG, Lin FY, Thiem VD, Trach DD, Trong ND, Mao ND, Hunt S, Schneerson R, Robbins JB, Chu C, Shiloach J, Bryla DA, Bonnet MC, Schulz D, Szu SC.
    Infect Immun; 2004 Nov; 72(11):6586-8. PubMed ID: 15501790
    [Abstract] [Full Text] [Related]

  • 4. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
    Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, Kossaczka Z, Bryla DA, Shiloach J, Robbins JB, Schneerson R, Szu SC.
    N Engl J Med; 2001 Apr 26; 344(17):1263-9. PubMed ID: 11320385
    [Abstract] [Full Text] [Related]

  • 5. Preparation and evaluation of immunogenic conjugates of Salmonella enterica serovar Typhi O-specific polysaccharides with diphtheria toxoid.
    Ali A, An SJ, Cui C, Haque A, Carbis R.
    Hum Vaccin Immunother; 2012 Feb 26; 8(2):189-93. PubMed ID: 22426380
    [Abstract] [Full Text] [Related]

  • 6. Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component.
    Wetter M, Kowarik M, Steffen M, Carranza P, Corradin G, Wacker M.
    Glycoconj J; 2013 Jul 26; 30(5):511-22. PubMed ID: 23053636
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Polysaccharide conjugate typhoid vaccine.
    Guerrant RL, Kosek M.
    N Engl J Med; 2001 Apr 26; 344(17):1322-3. PubMed ID: 11320392
    [No Abstract] [Full Text] [Related]

  • 10. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
    Fraillery D, Baud D, Pang SY, Schiller J, Bobst M, Zosso N, Ponci F, Nardelli-Haefliger D.
    Clin Vaccine Immunol; 2007 Oct 26; 14(10):1285-95. PubMed ID: 17687110
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Vi polysaccharide-protein conjugate vaccine for the prevention of typhoid fever in children: hope or hype?
    Pulickal AS, Pollard AJ.
    Expert Rev Vaccines; 2007 Jun 26; 6(3):293-5. PubMed ID: 17542742
    [No Abstract] [Full Text] [Related]

  • 14. A Salmonella typhi Vi conjugate vaccine.
    Koul PA.
    N Engl J Med; 2001 Aug 16; 345(7):545-6. PubMed ID: 11519517
    [No Abstract] [Full Text] [Related]

  • 15. Prophylactic potential of cytolethal distending toxin B (CdtB) subunit of typhoid toxin against Typhoid fever.
    Thakur R, Pathania P, Kaur N, Joshi V, Kondepudi KK, Suri CR, Rishi P.
    Sci Rep; 2019 Dec 05; 9(1):18404. PubMed ID: 31804525
    [Abstract] [Full Text] [Related]

  • 16. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
    Bhutta ZA, Capeding MR, Bavdekar A, Marchetti E, Ariff S, Soofi SB, Anemona A, Habib MA, Alberto E, Juvekar S, Khan RM, Marhaba R, Ali N, Malubay N, Kawade A, Saul A, Martin LB, Podda A.
    Lancet Infect Dis; 2014 Feb 05; 14(2):119-29. PubMed ID: 24290843
    [Abstract] [Full Text] [Related]

  • 17. Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRM197 conjugate vaccine.
    Micoli F, Bjarnarson SP, Arcuri M, Aradottir Pind AA, Magnusdottir GJ, Necchi F, Di Benedetto R, Carducci M, Schiavo F, Giannelli C, Pisoni I, Martin LB, Del Giudice G, MacLennan CA, Rappuoli R, Jonsdottir I, Saul A.
    Proc Natl Acad Sci U S A; 2020 Sep 29; 117(39):24443-24449. PubMed ID: 32900928
    [Abstract] [Full Text] [Related]

  • 18. Synthesis and some immunologic properties of an O-acetyl pectin [poly(1-->4)-alpha-D-GalpA]-protein conjugate as a vaccine for typhoid fever.
    Szu SC, Bystricky S, Hinojosa-Ahumada M, Egan W, Robbins JB.
    Infect Immun; 1994 Dec 29; 62(12):5545-9. PubMed ID: 7960137
    [Abstract] [Full Text] [Related]

  • 19. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
    Pakkanen SH, Kantele JM, Savolainen LE, Rombo L, Kantele A.
    Vaccine; 2015 Jan 09; 33(3):451-8. PubMed ID: 25433216
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.